

Robust Weighting Schemes, Longitudinal Growth Curves, and Unhealthy Subpopulations as Reference Databases

ASA Biopharmaceutical Section Statistics Workshop

Statistical Challenges for Medical Tests with Reference Databases

September 27, 2017

Paul S. Horn

Division of Neurology

Cincinnati Children's Hospital Medical Center

Examples of Reference Databases:

- May be either prospective or retrospective
- May be cross-sectional or longitudinal
- National Health and Nutrition Examination Survey (NHANES).
 - Conducted annually since 1999
 - Data released every 2 years
 - Contains strata, clusters, sampling weights
 - Subsample will be longitudinal
 - Re-contacting some who were examined 2007-2014

Examples (continued)

- Kid's Inpatient Database (KID).
 - Pediatric discharge data
 - Every 3 years starting 1997
 - 2015: Q1-Q3 ICD-9, Q4 ICD-10
 - 2016: ICD-10
 - Up to 15 diagnosis codes
 - All payers
 - Cost-to-Charge ratios at hospital level
- Has strata, clusters, sampling weights
- Not all states represented
- Comparing across years is an issue
- Can this be used as a reference sample?
 - Pediatric problem

KID: Comparing across years

- Consider $\bar{X}(2003)$ and $\bar{X}(2000)$
- With respective standard errors, $se(2003)$, $se(2000)$
- Simple \sim Z-statistic:

$$\frac{\bar{X}(2003) - \bar{X}(2000)}{\sqrt{se^2(2003) + se^2(2000)}}$$

- Z is probably smaller than it should be (conservative)
 - Denominator is missing $-2 * Cov((2003), (2000))$
- \bar{Z} is probably smaller than it should be (conservative)
 - Covariance is probably ≥ 0
 - Denominator is missing $-2 * Cov(\bar{X}(2003), \bar{X}(2000))$
 - Covariance is probably ≥ 0

Examples (continued)

- Framingham Heart Study (FHS)
 - Risk factors for heart disease -1948
 - Used for “cutting-edge heart, brain, bone, and sleep research”
- Private
 - Private laboratories.
 - Urine samples from prescription drug users.
 - Individual hospitals
 - CCHMC
 - Pulmonary function tests from boys with Duchenne’s Muscular Dystrophy (DMD).
 - Lean Body Mass from DMD boys.
 - Fernald Medical Monitoring Program (FMMP)
 - Nuclear fuel processing plant, Fernald, OH
 - Uranium and radon exposure
 - Monitor health of workers and families 1990-2008
 - “Healthy” individuals could be used as a reference sample

Reference Ranges a.k.a. Reference Intervals

- Requires database of “healthy” subjects
- Physician-determined
 - Independent of analyte measurements (FMMP)
- Convenience sample - volunteers
 - Screen for obvious exclusion factors
- Subpopulations of unhealthy
 - DMD

Types of Reference Intervals

- Nonparametric
 - Uses order statistics
- Gaussian-based
 - Based on prediction interval
 - Uses sample mean and standard deviation

$$\bar{x} \pm t_{\alpha/2}^{(n-1)} s \sqrt{1+1/n}$$

- Most likely requires transformation first
- Robust
 - Mimics Gaussian-based interval
 - Uses robust versions of center and spread

Robust reference interval (continued)

Gaussian: $\bar{x} \pm t_{\alpha/2}^{(n-1)} s \sqrt{1+1/n}$

$$T_{bi}(c_1) \pm t_{\alpha/2}^{(n-1)} \sqrt{S_T^2(c_1) + s_{bi}^2(c_2)}$$

where,


$T_{bi}(c_1)$ is location estimator based on the “biweight” function. (c_1 is a tuning constant)

$S_T^2(c_1)$ is an estimator of the variance of $T_{bi}(c_1)$

$s_{bi}(c_2)$ is an estimator of spread based on the biweight. (Note the different tuning constant, c_2)

Biweight smoothly “weights” observations.


- Values further from the center get smaller weights.
- Values very far away get zero weight.
- If weight = 1 for all values \square sample mean.
- If weight = 0 for all values, except middle value \square sample median.
- Iterative process starting at the sample median.



Iteration and reweighting:

- $T_{bi}^{(j)}$ at j^{th} iteration is just a weighted average
 - The weight for x_i is $w_i = (1 - u_i^2)^2$
 - Where $u_i = (x_i - T_{bi}^{(j-1)}) / (c * s)$
 - and c is the tuning constant, s is robust estimator of spread, e.g., MAD.
- Straightforward for simple random samples
- Must be careful if there are sampling weights, e.g., NHANES
 - Original biweight reference interval code was written with NHANES in mind
- Strata and clusters, e.g., KID


Example: Bilirubin from 3005 Boys < 12 yo



Source: Eli Lilly & Co.
Clinical Trial Data,
Beasley et al 2017.
Manuscript under
review.

95% Reference Limits	Nonparametric	90% CI	Robust	90% CI Bootstrap	Bca
Lower	0.2	0.2 - 0.2	0.17	0.171-0.174	0.171-0.174
Upper	0.9	0.9 - 1.0	0.87	0.838-0.896	0.836-0.895

Remove Outliers:



95% Reference Limits	Outliers Removed	Nonparametric	90% CI	Robust	90% CI Bootstrap	Bca
Lower	647 (= 0.2)	0.3	0.3-0.3	0.25	0.254-0.300	0.254-0.300
Upper	250 (≥ 0.7)	0.6	0.6-0.6	0.58	0.575-0.645	0.570-0.605


However,

- All of the above reference interval approaches are based on random samples of healthy subjects
- Complicating this is the fact that it is often the case that data are collected longitudinally
 - Forced to ignore blocking variable – subject
- We are often interested in an unhealthy subpopulation as it compares to an appropriate healthy reference
- Unhealthy subpopulation as a “reference”

LMS Growth Curves (TJ Cole, JRSS 1988)

Generalized Additive Models for Location, Scale, and Shape

R Library gamlss




Healthy Control
raw data, light
grey, is
longitudinal
(unpublished)

Circles are DMD boys' raw data – also longitudinal

Use Smoothing with Generalized Linear Models

- SAS Macro radial_smoothing_percentile
 - PROC GLIMMIX
- Can only have one continuous covariate – usually age
- “Nonparametric estimation of age-specific reference percentile curves with radial smoothing” X Wan, Y Qu, Y Huang, X Zhang, H Song, and H Jiang. Contemporary Clinical Trials 33 (2012): 13-22

Deciles for DMD Boys: Forced Vital Capacity % (unpublished)



Longitudinal data.

Upper ages based on only a few subjects


No data available for healthy controls

Urine Drug Testing - Provided by Amadeo Pesce

- Used to determine medication compliance
- Use of non-prescription and illicit drugs
- Most insurers prefer to pay for qualitative testing
- Quantification of the urine drugs allows for more extensive investigations
 - Data could serve as a reference sample
 - But no info within subject
- In October 2014 DEA:
 - Hydrocodone moved from Schedule III to Schedule II
 - Thus, prescriptions could no longer be called in
- Concentration of Hydrocodone should decrease over time

Compare October 2015 and October 2016


- Hydrocodone – Now Schedule II - Change
 - 2015: n = 2394, mean(SD) = 1206 (2449) ng/mL
 - 2016: n = 2882, mean(SD) = 1489 (4726) ng/mL
 - T-test p-value < 0.001, many outliers
 - Wilcoxon p-value = 0.03, but mean score in 2015 > 2016



- Kolmogorov-Smirnov p-value = 0.0003
 - EDF at maximum: 2016 > 2015

Compare October 2015 and October 2016

- Oxycodone – Still Schedule II - No change
 - 2015: n = 1822, mean(SD) = 5543 (23464) ng/mL
 - 2016: n = 3300, mean(SD) = 5344 (29642) ng/mL
 - T-test p-value = 0.80
 - Wilcoxon p-value = 0.57



- Kolmogorov-Smirnov p-value = 0.70

Closing Remarks

- How to define “healthy” in a reference database?
- Properties of the data collection
 - Strata
 - Clusters
 - Participating hospitals, states, etc. (e.g., KID)
- How to incorporate covariance structure for age-dependent reference curves?
- Privacy, HIPAA, public policy, etc., may affect ability to do correct statistical analysis